At the time of writing, Summit Therapeutics Inc [SMMT] stock is trading at $22.93, up 7.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SMMT shares have gain 3.52% over the last week, with a monthly amount glided 21.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Underweight rating and assigned the stock a price target of $13. Previously, Guggenheim started tracking the stock with Buy rating on September 04, 2025, and set its price target to $40. On August 19, 2025, Piper Sandler initiated with a Neutral rating and assigned a price target of $21 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $30 on July 01, 2025. Leerink Partners initiated its recommendation with a Underperform and recommended $12 as its price target on June 11, 2025. Citigroup upgraded its rating to Buy for this stock on March 26, 2025, and upped its price target to $35. In a note dated March 21, 2025, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Summit Therapeutics Inc fluctuated between $15.55 and $36.91. Currently, Wall Street analysts expect the stock to reach $32.75 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $22.93 at the most recent close of the market. An investor can expect a potential return of 42.83% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.3, Equity is -2.09 and Total Capital is -2.88. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Summit Therapeutics Inc [NASDAQ:SMMT] has a current ratio of 5.13. Further, the Quick Ratio stands at 5.13, while the Cash Ratio is 4.94.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Co-Chief Executive Officer, that happened on Sep 10 ’25 when 0.33 million shares were purchased. Co-Chief Executive Officer, Zanganeh Mahkam completed a deal on Sep 11 ’25 to buy 5000.0 shares. Meanwhile, Co-Chief Executive Officer DUGGAN ROBERT W bought 0.33 million shares on Sep 10 ’25.
